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Carcinoma-associated pancreatic fibroblasts (CAFs) are the major type of cells in
the stroma of pancreatic ductal adenocarcinomas and besides their pathological
release of extracellular matrix proteins, they are also perceived as key contributors
to immune evasion. Despite the known relevance of tumor infiltrating lymphocytes in
cancers, the interactions between T-cells and CAFs remain largely unexplored. Here,
we found that CAFs isolated from tumors of pancreatic cancer patients undergoing
surgical resection (n = 15) expressed higher levels of the PD-1 ligands PD-L1 and
PD-L2 compared to primary skin fibroblasts from healthy donors. CAFs strongly
inhibited T-cell proliferation in a contact-independent fashion. Blocking the activity of
prostaglandin E2 (PGE2) by indomethacin partially restored the proliferative capacity of
both CD4+ and CD8+ T-cells. After stimulation, the proportion of proliferating T-cells
expressing HLA-DR and the proportion of memory T-cells were decreased when CAFs
were present compared to T-cells proliferating in the absence of CAFs. Interestingly,
CAFs promoted the expression of TIM-3, PD-1, CTLA-4 and LAG-3 in proliferating
T-cells. Immunohistochemistry stainings further showed that T-cells residing within
the desmoplastic stromal compartment express PD-1, indicating a role for CAFs on
co-inhibitory marker expression also in vivo. We further found that PGE2 promoted the
expression of PD-1 and TIM-3 on T-cells. Functional assays showed that proliferating
T-cells expressing immune checkpoints produced less IFN-γ, TNF-α, and CD107a after
restimulation when CAFs had been present. Thus, this indicates that CAFs induce
expression of immune checkpoints on CD4+ and CD8+ T-cells, which contribute to a
diminished immune function.
Keywords: cancer-associated pancreatic stellate cells, fibroblasts, pancreatic cancer, T-cells, co-inhibitory
markers, PD-1, TIM-3
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INTRODUCTION
The late diagnosis and the lack of an effective treatment brings
pancreatic cancer to the fourth leading cause of cancer-related
death, with a 5-year survival rate of only 6% (1). During the last
decade, immunotherapy drugs have offered significant benefit
for certain malignancies including melanoma, lung cancer, and
head and neck cancer, but it has so far been unsuccessful for
pancreatic cancer patients (2, 3). The failure of developing a
successful treatment is due in part to the limited understanding
of the complex microenvironment in the pancreatic tumor.
The most common form of pancreatic cancer, pancreatic
ductal adenocarcinoma (PDAC), is characterized by a
voluminous desmoplastic reaction mediated by carcinoma
associated pancreatic stellate cells and other cancer-associated
fibroblasts (CAFs). Under normal conditions, pancreatic stellate
cells have a limited proliferative capacity and store vitamin A
containing lipid droplets in their cytoplasm. In the presence
of cancer cells, pancreatic stellate cells acquire an increased
contractile ability which promotes the expression of α-smooth
muscle actin (α-SMA), podoplanin and the loss of their
characteristic cytoplasmic lipid droplets which results in the
pathological release of extracellular matrix proteins triggering
fibrosis and building a “wall” for therapy delivery (4). Therefore,
the presence of large amounts of CAFs are associated with poor
prognosis (5). Recent studies also suggest that there are several
subtypes of CAFs in pancreatic cancer that may play different
roles in the tumor microenvironment (6–8).
The importance of CAFs in tumors has mainly been studied
in the context of interactions with tumor cells (9, 10). CAFs
express the catabolic enzyme indoleamine 2,3-dioxygenase (IDO)
and release a variety of factors such as transforming growth
factor- β (TGF- β), vascular endothelial growth factor (VEGF),
interleukins (IL)-6, IL-1 and IL-8, and prostaglandin E2 (PGE2)
that directly or indirectly participate in the development of
an immunosuppressive tumor milieu that promote tumor
growth, angiogenesis and metastasis (10). However, a growing
number of studies perceive fibroblasts as key contributors
of immune evasion and show the direct interplay between
fibroblasts and immune cells. Cancer associated fibroblasts
(CAFs) induce T-regulatory cells as well as T-cell apoptosis in
head and neck squamous cell carcinoma (11), modulate natural
killer cell functions in melanoma (12), educate dendritic cells
into regulatory cells in hepatic carcinoma (13) and induce
protumoral M2 macrophages in PDAC (14). However, the
interactions between CAFs and T-cells in pancreatic cancer
remain largely unexplored.
The presence of both CD4+ and CD8+ tumor infiltrating
T lymphocytes (TILs) is a predictor of long term survival
in PDAC (15, 16). However, in the majority of cases
cancer cells readily evade immune surveillance with the
help of immune checkpoints. The general notion is that
the chronic stimulation by tumor antigens and the exposure
of suppressive cytokines, drive TILs to differentiate into an
exhausted phenotype characterized by the expression of immune
checkpoint molecules such as programmed cell death-1 (PD-
1), T-cell immunoglobulin and mucin-domain containing-3
(TIM-3), lymphocyte-activation gene- 3 (LAG-3), cytotoxic
T-lymphocyte-associated antigen-4 (CTLA-4), and T-cell Ig
and ITIM domain (TIGIT). These exhausted T-cells have a
diminished proliferative ability and lose their cytotoxic functions
(17). Supporting this evidence a recent study shows that high
levels of CD8+ PD-1+ TILs is correlated with poor prognosis and
shorter overall survival in PDAC (18).
The fact that the T-cells can be held back by the tumor
stroma in pancreatic cancer (19, 20) suggests that CAF-
derived factors may be able to modulate T-cell functions and
phenotype. Here, through a series of in vitro experiments
we demonstrated that CAFs induce expression of immune-
checkpoints on CD4+ and CD8+ T-cells, which contribute to a
diminished immune function.
MATERIAL AND METHODS
Patients and Samples
Pancreatic tumor tissues were collected from 15 patients
undergoing surgery at the Pancreatic Surgery Unit at Karolinska
University Hospital, Huddinge, Sweden (Table 1). Thirteen of
the patients had PDAC, one had adenosquamous carcinoma of
the pancreas and one had colloid carcinoma of the pancreas.
Primary normal skin fibroblasts were obtained from healthy
donors and peripheral blood samples were collected from healthy
blood donors. Written informed consent was obtained from
the patients. The study was approved by the regional review
board of ethics in research of Karolinska Institutet (entry nos.
2009/418-31/4, 2013/977-31.3, and 2017/722-32).
Cell Isolation
For isolation of pancreatic CAFs, a similar outgrowth method
as first described by Bachem et al. was used (21). Freshly
resected pancreatic tumor tissues were cut into small pieces
and cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(GE Healthcare, cat no. SH3002101) supplemented with 10%
fetal bovine serum (HyClone, cat no. SV3016003) and 1%
penicillin-streptomycin (HyClone, cat no. SV30010) (complete
DMEM) in 6 well plates. Fibroblasts were let to migrate
out the tissue fragments for 15–20 days and then cells were
harvested with trypsin-EDTA (HyClone, cat no. SH3023602)
and transferred to T75 or T175 flasks for further expansion.
Skin-derived fibroblasts were isolated from punch biopsies in
the same fashion. Cells were expanded until passage 3 and
then cryopreserved in complete DMEM with 10% dimethyl
sulfoxide (GmbH cat no. WAK-DMSO-70) until analysis. Before
the experiments, cells were thawed in complete DMEM medium
and characterized by flow cytometer using the antibodies shown
in Supplementary Table S1. Peripheral blood mononuclear cells
(PBMCs) were isolated from buffy coats from healthy donors and
patients by density gradient over LymphoprepTM gradient (Axis
Shield, cat no. 1114547).
Proliferation Assays
PBMCs were labeled with carboxyfluorescein succinimidyl ester
(CFSE) (Molecular Probes, Life Technologies, cat no. C34554)
(5µg/ml) in PBS at 37◦C for 15min. After washing, the cells were
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TABLE 1 | Patient characteristics.
Variables n = 15
DEMOGRAPHIC CHARACTERISTICS
Age, years
Female gender, n 8
Median age, years (range) 64 (55–82)
Male gender, n 7
Median age, years (range) 52 (34–78)
ONCOLOGIC CHARACTERISTICS
Histological type
Pancreatic ductal adenocarcinoma, n 13
Adenosquamous carcinoma, n 1
Colloid carcinoma of the pancreas, n 1
Tumor size, cm
>2 and ≤5 11
>5 4
Tumor depth, n
T3 13
T4 2
Lymph node metastasis, n
N0 1
N1 14
Metastasis, n
M0 12
M1 3
Chemotherapy (FOLFOX), n
Yes 3
No 12
T (3,4), Tumor stage; N1, lymph node with cancer; M1, Distant metastasis.
plated in 96-well plates (2 × 105), 24-well plates (1 × 106), or
12-well plates (2 × 106) (Corning) in the presence or absence
of 30Gy irradiated CAFs at a 1:10 ratio (1 CAF per 10 PBMCs).
The culture medium used was RPMI-1640 (HyClone, cat no.
SH3025501) supplemented with 10% human AB serum and
1% penicillin-streptomycin. PBMCs were stimulated with OKT3
(25 ng/ml) (Biolegend, cat no. 317315) or left unstimulated.
To prevent contact between fibroblasts and PBMCs, a 12-well
Transwell system [0.4µm pore size membrane (Corning)] was
used for a set of experiments. Fibroblasts were added to the
upper chamber and PBMCswere added to the lower chamber. On
day 5, PBMCs were harvested and analyzed by flow cytometry.
The majority of the proliferation assays were performed with
allogeneic PBMCs, but a number for experiments were done with
PBMCs and CAFs derived from the same patient.
Blocking experiments were performed in 96-well plates
and 20µM indomethacin [(Sigma-Aldrich, cat no. I7378)
for PGE2 blocking], 1mM 1-methyl-DL-tryptophan [(Sigma
Aldrich, cat no. 860646) for IDO blocking], 10µg/ml anti-PD-
L1 and 10µg/ml anti-PD-L2 (BioLegend cat no. 329710 and
345504), 5µg/ml anti-TGF-β (R&D systems, cat no. MAB246)
or the appropriate isotypes [IgG1/IgG2b (R&D systems, cat no.
MAB002 and MAB004)] or vehicles were added to the cell
cultures. To control for the effect that these substances may
have on the proliferative response of T-cells in the absence of
CAFs, a ratio of the response of T-cells in the presence and
absence of CAFs was calculated for the control and the blocking
conditions, respectively.
To study the interactions between CAFs, tumor cells, and
PBMCs, we used the pancreatic tumor cell line PANC-1. The
experiments were performed as described above, including
irradiation of PANC-1 cells and CAFs at 30Gy, but the CAFs or
PANC-1 cells were added at a ratio of 1 cell per 20 PBMCs (1:20).
For intracellular detection of cytokines, 25 ng/ml PMA,
1µg/ml ionomycin, 10µg/ml Brefeldin-A (Sigma-Aldrich, cat
no. 79346, I0634, and B7651), and Golgi Stop (diluted 1:1,500,
BD Biosciences, cat no. 554715) were added. PGE2 (0.1µg/ml,
Sigma Aldrich, cat no. P0409) was added to PBMC cultures for a
set of experiments.
Flow Cytometry
A list for the antibodies used in this study is shown in
Supplementary Table S1. Extracellular staining was performed
in CliniMACS PBS/EDTA buffer (Miltenyi Biotech cat no.
200-070-025) supplemented with 0.1% bovine serum albumin.
Extracellular markers were analyzed on viable cells (7-AAD
negative). Intracellular staining of α-SMA, IFN-γ, and TNF-
α was performed using the BD Cytofix/CytopermTM kit (BD
Biosciences, cat no. 554714) according to the manufacturer’s
instructions. Intracellular staining for FOXP3 was done with
FOXP3 staining buffer set (eBioscience, cat no. 0052300)
according to the manufacturer’s instructions. Phycoerythrin (PE)
conjugated CD107a was added in the cell cultures together with
PMA/I, Brefeldin A, and GolgiStop on day 5 for 6 h. Boolean
gating strategy was used to study the frequency of CD4+ and
CD8+ T-cells that were triple positive for TIM-3, PD-1 and
CTLA-4 or for TIM-3, PD-1, and LAG-3. A FACSCanto (BD) was
used for data acquisition and FlowJo (Tree Star, Ashland, OR,
USA) version 10.2 was used for data analysis. Sub-gating for all
analyzed samples was done with more than 100 events, and no
data points were excluded due to low events.
Immunohistochemistry Stainings
Fresh tumor tissue was sampled by specialized pancreatic
pathologists immediately after surgical resection. The tissue
sample was divided in two pieces: one was put in culture
medium and sent for cell isolation, while the other was
fixed in 4% formalin, embedded in paraffin and processed
for histology and immunohistochemistry as matched reference
tissue. Four µm thick sections were immunohistochemically
stained using a Leica BOND III automated immunostainer. The
antibody panel consisted of CD3 (clone LN10, manufacturer
Novocastra, product code NCL-L-CD3-565, dilution 1:100), α-
SMA (1A4, Dako, M0851, 1:500) and PD-1 (NAT105, Cell
Marque, 315M-96, 1:100). CD3 and α-SMA were combined by
duplex immunohistochemistry and stained using DAB (brown)
respective AP (red) chromogens to better visualize the spatial
relation between T-cells and CAFs.
Quantitative analysis of CD3+ and PD-1+ cells was performed
on the whole slide images using QuPath (22). Briefly, four
rectangular regions of equal size containing tumor cells and
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stroma, but not benign ducts or acinar tissue, were defined on
each CD3 and α-SMA stained slide. The tumor regions were
annotated manually and validated by a specialized pancreatic
pathologist (CFM). The rectangular regions for quantification
and the tumor annotations within the regions were transferred
to, corrected where needed, and validated in the matched PD-
1 stained slides. Afterwards, the several tumor annotations
were combined and a stroma annotation was derived for each
quantification region. Tissue areas and cells were detected and
quantified for each region. The cells positive for CD3 or PD-
1, respectively, according to DAB staining, were classified as
residing within the tumor nests or within the stroma according to
the annotation regions. Finally, the positive cells close to tumor
cells were identified using Delaunay triangulation with a distance
of 20µm. Quantitative data was exported in a tabular format for
descriptive statistical analysis. An overview of the image analysis
pipeline is provided in Supplementary Figure S7.
ELISA
Concentrations of IL-10 were measured in the supernatants
obtained after co-cultures with an in-house ELISA, using an
anti-human IL-10 coating antibody (R&D, cat no. MAB2172), a
secondary biotinylated goat anti-human IL-10 antibody (R&D,
cat no. BAF217), a standard of recombinant human IL-10 (R&D,
cat no. 1064-IL), and horseradish peroxidase (Sanquin, cat no.
M2032) for the enzymatic reaction.
Statistical Analysis
To detect differences across two groups, Wilcoxon matched-
pairs signed rank test was used. Data are expressed as the
median. To study differences between more than two groups, a
Friedman’s test followed by Dunn’s test was used. Correlations
between proliferation and expression of markers was performed
by Spearman correlation test. A p-value of< 0.05 was considered
statistically significant. All statistics were done using GraphPad
Prism version 7 (La Jolla CA, USA).
RESULTS
Characterization of Cancer Associated
Pancreatic Fibroblasts
The phenotype of primary CAFs was characterized by flow
cytometry and compared to normal skin fibroblasts. Both
types of fibroblasts were positive for the common stromal
markers CD29, CD44, CD73, CD90, and CD105, but negative
for the endothelial marker CD31 and the epithelial marker
EPCAM (Figure 1A). CAFs and skin fibroblasts were both
negative for VCAM, CD86 and HLA-DR, but positive for
ICAM-1 and HLA class I (Figure 1A). However, only CAFs
were positive for α-SMA (p < 0.0001) with a median
expression of 62% (Figures 1A,B). The expression of both
PD-L1 (p = 0.001) and PD-L2 (p = 0.01) was also
higher in CAFs compared to skin fibroblasts (Figures 1A,B).
We also noted that the expression of PD-L2 was generally
higher compared to PD-L1 in both CAFs and normal skin
fibroblasts. There was no statistically significant difference in
the expression levels of fibroblast activation protein (FAP)
and podoplanin (Figures 1A,B), which are markers known
to be associated with cancer. To examine if the phenotype
of CAFs is altered during serial passaging, the phenotype of
CAFs from 3 to 6 donors were compared between passage
1, 2 and 3. No consistent difference was observed for the
expression of α-SMA, PD-L1, PD-L2, or podoplanin at different
passages (Supplementary Figure S1). The morphology of the
isolated CAFs can be seen in a representative microphotograph
in Figure 1C.
Proliferative Capacity and Functionality of
T-Cells Are Compromised in the Presence
of CAFs
To study how CAFs affect the proliferative response of
T-cells, CFSE-labeled PBMCs from healthy donors were
cultured in the presence or absence of irradiated patient-
derived CAFs and stimulated or not with OKT3 for 5 days.
The presence of CAFs significantly reduced the proliferation
of CD4+ (p < 0.0001) and CD8+ (p < 0.0001) T-cells
(Figure 2A). This effect was mediated in a dose-dependent
manner (Supplementary Figure S2A). T-cell proliferation was
not induced by CAFs alone (Figure 2A). To clarify whether
the MHC mismatch between the PBMCs and CAFs is affecting
the assay, a number of experiments were done with autologous
PBMCs. The same effect was seen when PBMCs from patients
were co-cultured with autologous CAFs derived from the same
patients (Figure 2B).
To determine whether the observed immunosuppressive
effects of CAFs were mediated in a contact dependent or
independent fashion, CFSE-labeled PBMCs were cultured in
direct contact with CAFs or separated by a transwell membrane.
As shown in Figure 2C, no significant differences were found
in the level of inhibition of CD4+ and CD8+ T-cells between
the two conditions, indicating that the suppression is mainly
mediated by soluble factors.
To examine whether the immunomodulatory properties of
CAFs derived from PDAC differed from CAFs isolated from
colloid carcinoma and adenosquamous carcinoma (Table 1), we
co-cultured the different types of CAFs paired with the same
PBMC donors. The CAFs derived from the other types of
pancreatic cancer displayed a similar effect on T-cell proliferation
and co-inhibitory markers expression as observed for the CAFs
isolated from PDAC (Supplementary Figures S3A–E).
COX-2 Is Involved in the Immune
Regulatory Functions of Pancreatic CAFs
Next, we investigated whether the immune suppressivemolecules
PGE2, TGF-β, IDO, and PD-L1/L2, that previously have been
described to be expressed by carcinoma fibroblasts (23–25), were
involved in pancreatic CAF-mediated suppression. By inhibiting
PGE2 production with the COX-2 inhibitor indomethacin, CD4+
and CD8+ T-cell proliferation was partially restored in all paired
samples (n = 13) (Figure 2D). Blockade of the PD-1 pathway
with anti-PD-L1 and PD-L2 antibodies significantly restored
CD4+ T-cell proliferation and was restored in over half of the
experiments for CD8+ T-cells (11 out of 17) (Figure 2E). We
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FIGURE 1 | Phenotypic analysis of carcinoma associated pancreatic stellate cells (CAFs) and normal skin fibroblasts (NSFs) by flow cytometry. (A) Representative
histograms showing different CAFs (gray) and NSFs (white) molecules expression compared to FMO controls (dashed line). (B) Comparison of α-SMA, PD-L1, PD-L2,
FAP and podoplanin expression between CAFs (black dots) (n = 8–15) and NSFs (open triangles) (n = 5). (C) Representative image showing the morphology of CAFs
at passage 3 (Original magnification ×10). All fibroblasts were characterized in passage 3. The bars indicate the median. Wilcoxon matched-pairs signed rank test
was used to detect statistically significant differences *P < 0.05, **P < 0.01, ***P < 0.001.
found no correlation between efficacy of PD-L1 and PD-L2
blockade and the expression levels of these proteins in CAFs
(data not shown). By blocking TGF-β with neutralizing anti-
TGF-β antibodies or IDO with 1-D/L-MT, T-cell proliferation
was not significantly restored (Figures 2F,G). To examine if
the combined blocking of the COX-2 and PD-1 axis would
further abrogate the CAF-mediated suppression on T-cells, we
performed a set of experiment using indomethacin, anti-PD-
L1/L2 antibodies or both. Again, COX-2 inhibition increased
the proliferation for CD4+ and CD8+ T-cells (median 2.7-
fold and 1.8-fold, respectively), whereas blockade of PD-L1 and
PD-L2 only marginally increased the proliferation (median 1.2-
fold for CD4+ and 1.1-fold for CD8+) (Figure 2H). When
combining inhibition of both the COX-2 and PD-1 axis, no
increased effect on T-cell proliferation was observed (Figure 2H).
Overall, since one of the main functions of the COX-2 inhibitor
indomethacin is to block PGE2 synthesis, our data suggests
that PGE2 was one important factor involved in the CAF-
mediated anti-proliferative capacity on T-cells. PD-L1 and PD-
L2 probably also play a role in suppressing T-cell proliferation
in this setting, although this pattern was only significant for
CD4+ T-cells.
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FIGURE 2 | CAFs inhibit T-cell proliferation, but COX-2 inhibition partially restores T-cells proliferation. CFSE-labeled PBMCs were co-cultured in the absence (•) or
presence (N) of CAFs and stimulated with OKT3 (25 ng/ml) for 5 days. (A) Frequency of proliferating CD4+ and CD8+ T-cells in the absence or presence of allogeneic
CAFs in unstimulated (n = 14) and stimulated (n = 18) conditions (left). Representative CFSE histograms on CD4+ T-cells (right). (B) Frequency of proliferating
patient-derived CD4+ and CD8+ T-cells in the absence or presence of autologous CAFs (n = 3). (C) Frequency of proliferating CD4+ and CD8+ T-cells in direct
co-cultures (N), indirect transwell cultures ( ) or without allogeneic CAFs (•) (n = 12) (left). Representative CFSE histograms on CD4+ T-cells (right). (C–F) Proliferating
CD4+ and CD8+ T-cells was measured by flow cytometry after addition of corresponding isotype control or vehicle (N) or the following blocking substances (•); (C)
indomethacin to inhibit PGE2 production (n = 13), (D) anti-PD-L1 and anti-PD-L2 antibodies (n = 17), (E) anti-TGF-β antibodies (n = 8), or (F)
1-methyl-DL-tryptophan (1-D/L-MT) to inhibit indoleamine 2,3-dioxygenase (IDO) activity (n = 8). (H) COX2 inhibition, PD-L1 and PD-L2 blockade or combined of
both pathways (n = 5). (A,C) The bars indicate the median. (B,D–H) Lines between dots indicate paired samples. Data are related to those of the control cultures
without CAFs. Wilcoxon matched-pairs signed rank test was used to detect statistically significant differences between paired samples in the absence or presence of
CAFs, and between cultures with isotype or vehicles and cultures with the different immunomodulatory factors neutralized, *P < 0.05, ***P < 0.001, ns, not significant.
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Pancreatic CAFs Upregulate the
Expression of FOXP3 in Unstimulated
CD4+ T-Cells
CAFs from other types of cancers have previously been shown
to induce regulatory T-cells (Tregs) (11, 26). Our results also
showed a significant increase in FOXP3-expressing cells among
CD4+ T-cells when PBMCs were cultured in the presence of
CAFs without further stimulation. This was observed in both
direct co-cultures (median 2.3%) and indirect transwell cultures
(median 1.8%) conditions compared to PBMCs cultured alone
(median 1 and 0.7%, respectively) (Supplementary Figure S4A).
CAFs also induced a significant increase in IL-10 levels in
the supernatants, which was most pronounced when cell-
cell contact was allowed (Supplementary Figure S4B). CAFs
alone did not produce IL-10, suggesting that PBMCs were the
source of IL-10, but it is also possible that IL-10 could be
produced by CAFs after receiving signals derived from PBMCs
(Supplementary Figure S4B). No significant correlation was
observed between the proportion of FOXP3+ in CD4+ T-cells
and the levels of IL-10 in the supernatant (data not shown).
Pancreatic CAFs Upregulate the
Expression of Immune Checkpoints on
Proliferating T-Cells
Since the tumor microenvironment promotes expression of co-
inhibitory markers on T-cells, we next sought to examine if
pancreatic CAFs are involved in altering the expression of these
receptors. We investigated how CAFs affect the expression of
five co-inhibitory receptors on activated proliferating T-cells.
We found that the expression of TIM-3 (Figures 3A,B), PD-1
(Figures 3A,C) and CTLA-4 (Figures 3A,D) were higher in the
presence of CAFs on both CD4+ and CD8+ T-cells in a dose-
dependent manner (Supplementary Figures S2B–E) compared
to the T-cells cultured in the absence of CAFs. The frequency of
LAG-3 expression was increased in CD4+ T-cells (Figures 3A,E),
while the levels of TIGIT expression was lower on CD8+ T-
cells in the presence of CAFs (Figures 3A,F). The co-expression
of TIM-3 and PD-1 (Figures 3A,G), TIM-3, PD-1 and CTLA-
4 (Figure 3H) and TIM-3, PD-1, and LAG-3 (Figure 3I) were
also higher in the presence of CAFs. Interestingly, the up-
regulation of co-inhibitory markers did not coincide with a
higher expression of the late activation marker HLA-DR, which
was lower in the presence of CAFs on both CD4+ and CD8+
proliferating T-cells (Figures 3A,J) in a dose-dependent manner
(Supplementary Figure S2E). The same tendency was observed
when patient-derived PBMCs were co-cultured with autologous
CAFs (Figure 3K).
The up-regulation of co-inhibitory markers on T-cells
was at least partially mediated by soluble factors since no
significant differences were found on the expression of
TIM-3, LAG-3 and CTLA-4 on CD4+ or CD8+ T-cells
in transwell cultures conditions compared to direct co-
cultures (Supplementary Figures S5A,B,D–F). Additionally,
no difference were observed for HLA-DR expression
(Supplementary Figure S5G). Only PD-1 expression was lower
on CD4+ and CD8+ T-cells in transwell cultures compared to
co-cultures, although PD-1 expression was still higher compared
to activated PBMC alone (Supplementary Figure S5C).
Immunoregulatory Functions of CAFs and
Pancreatic Tumor Cells in Combination
Next, we examined how CAFs and tumor cells in combination
would affect T-cell proliferation and expression of co-inhibitory
markers. Overall, as shown by the connecting lines, both
CAFs and PANC-1 inhibited CD8+ T-cells proliferation
(Supplementary Figure S6A) and upregulated the co-inhibitory
markers PD-1, TIM-3 and LAG-3 compared to activated
T-cells cultured alone (Supplementary Figures S6B–D).
However, by using multiple comparison tests, there was a
stronger inhibitory effect of CAFs on T-cells proliferation
compared to PANC-1 cells (Supplementary Figure S6A).
Moreover, the upregulation of the expression of the co-inhibitory
markers TIM-3 and LAG-3 on proliferating T-cells was
greater in the presence of CAFs compared to PANC-1 cells
(Supplementary Figures S6C,D). Finally, the expression of
HLA-DR was more inhibited in the presence of CAFs compared
to PANC-1 (Supplementary Figure S6F).
When both CAFs and PANC-1 were added to the PBMC
cultures, the immunomodulatory effects were enhanced, further
inhibiting T-cell proliferation and upregulating PD-1 expression
and the co-expression of PD-1 and TIM-3 on proliferating T-
cells (Supplementary Figures S6A,B,D–F). This might suggest
a possible crosstalk between CAFs and cancer cells that leads
to an even stronger upregulation of inhibitory factors. However,
further functional experiments are needed to confirm this.
Localization of T-Cells and PD-1+ Cells in
α-SMA+ Desmoplastic Tumor Stroma
To corroborate the localization of PD-1+ T-cells in pancreatic
tumors, we performed immunohistochemistry stainings of
central tumor tissues from three donors, two with pancreatic
ductal adenocarcinoma and one with colloid carcinoma of the
pancreas. In all three cases, the tumor nests were surrounded
by a dense α-SMA+ desmoplastic stroma (Figure 4A). T-cells
were present in the tissues, but they were primarily found in the
stroma with few T-cells infiltrating the tumor nests (Figure 4A).
Stainings of consecutive slides further revealed that T-cells
residing within the stroma expressed PD-1 (Figure 4B).
To quantify the number and location of the T-cells and
PD-1+ cells within the tumor nests and stroma, we the used
the QuPath software to analyze the immunohistochemistry
stainings. A step-by-step description of the analysis is shown
in Supplementary Figure S7. From each slide, we quantified
the number of cells in four different areas. The data retrieved
from the analysis is shown in Table 2. The proportion of CD3+
T-cells among total number of nucleated cells in these areas
varied between 2.6 and 26%, and the proportion of PD-1+ cells
between 0.5 and 2.1% (Table 2). When quantifying the number
of T-cells and PD-1+ cells in tumor and stroma, we found that
both T-cells and PD-1+ cells were more numerous per mm2 in
the stroma compared to the tumor nests in all three patients
(Figure 4C and Table 2). Consequently, a larger proportion of all
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FIGURE 3 | CAFs promote the expression of co-inhibitory markers on proliferating T-cells. CFSE-labeled PBMCs were co-cultured in the absence (•) or presence (N)
of CAFs and stimulated with OKT3 (25 ng/ml) for 5 days. (A) Representative flow cytometry dot plots on proliferating CD4+ T-cells showing the expression of different
molecules after stimulation in the presence or absence of allogeneic CAFs. Expression of (B) TIM-3 (n = 18), (C) PD-1 (n = 18), (D) CTLA-4 (n = 8), (E) LAG-3
(n = 12), (F) TIGIT (n = 8), (G) co-expression of TIM-3 and PD-1 (n = 16), (H) co-expression of TIM-3, PD-1 and CTLA-4 (n = 6) and (I) co-expression of TIM-3, PD-1
and LAG-3 (n = 12), and (J) HLA-DR (n = 18) on proliferating CD4+ and CD8+ T-cells in the absence (•) or presence (N) of allogeneic CAFs. (K) Co-inhibitory
markers on patient-derived CD4+ and CD8+ T-cells in the absence or presence of autologous CAFs (n = 3). (A–J) The bars indicate the median. (K) Lines between
dots indicate pared samples. Wilcoxon matched-pairs signed rank test was used to detect statistically significant differences, *P < 0.05, **P < 0.01, ***P < 0.001.
CD3+ T-cells in the examined tissue was located to the stromal
compartment, ranging between 94 and 96% of all detected T-cells
(Figure 4D). Likewise, the percentage of all PD-1+ cells was also
higher in the stroma compared to the tumor nests (Figure 4D).
We next investigated if inclusion of T-cells in close proximity
to the tumor cells (20µm), which potentially could mediate
anti-tumor effects, would change the delineation of the density
T-cells in contact with tumor cells. As shown in Figure 4D, we
found that including the cells in close proximity to tumor cells
marginally changed the proportion of T-cells localized to the
stroma. A very similar pattern was observed for PD-1 expressing
cells (Figure 4D). These data suggest that the majority of T-
cells in the pancreatic tumor microenvironment are trapped
in the stromal compartment, with little interaction with tumor
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FIGURE 4 | Localization of T-cells and PD-1+ cells in α-SMA+ desmoplastic tumor stroma. (A) Microphotographs of representative tumor areas from three different
patients showing abundant desmoplastic stroma composed of α-SMA+ CAFs (red) with foci of CD3+ T-cells (brown). In these three patients, most of the T-cells were
localized in the stroma with little direct cell-cell contact with adjacent adenocarcinoma cells. Second row of sample from patient 2 (a patient with colloid carcinoma of
the pancreas) illustrates a peritumoral tertiary lymphoid structure. (B) Consecutive slides stained for PD-1 (brown) show abundant expression of PD-1 in T-cell rich
areas within the desmoplastic stromal compartment. (C) Number of CD3+ T-cells and PD-1+ cells per mm2 in stroma and tumor nests in 4
annotations.(D) Percentage of CD3+ and PD-1+ cells detected in the stroma, in the stroma without close interaction with the tumor (20µm), in the tumor nest, and in
the tumor nest including positive cells in close proximity to the tumor (20µm).
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TABLE 2 | Computational analysis of immunohistochemistry stainings.
Patient 1 Patient 2 Patient 3
Number of annotations 4 4 4
Total number of nucleated cells* 22,753 15,537 20,447
20,159 14,970 18,752
Total tumor area (mm2)* 0.62 0.48 0.90
0.64 0.49 0.85
Total stroma area (mm2 )* 3.4 3.5 3.1
3.4 3.5 3.1
Number of CD3+ cells in total area 919 4,065 543
Number of PD-1+ cells in total area 180 1,226 94
Number of CD3+ cells per mm2 in tumor 65 285 38
Number of CD3+ cells per mm2 in stroma 260 1,115 164
Number of PD-1+ cells per mm2 in tumor 24 49 1
Number of PD-1+ cells per mm2 in stroma 49 342 29
Percentage CD3+ cells of all nucleated cells in total area (%) 4.0 26.2 2.7
Percentage PD-1+ cells of all nucleated cells in total area (%) 0.89 8.2 0.50
Percentage of CD3+ cells in tumor (%) 4.4 3.3 6.3
Percentage of CD3+ cells in and close to tumor (20µm) (%) 9.7 5.9 10.1
Percentage of CD3+ cells in stroma (%) 95.6 96.7 93.7
Percentage of CD3+ cells in stroma, not close to tumor (20µm) (%) 90.3 93.6 89.1
Percentage of PD-1+ cells in tumor (%) 8.3 2.0 1.1
Percentage of PD-1+ cells in and close to tumor (20µm) (%) 11.7 5.0 3.2
Percentage of PD-1+ cells in stroma (%) 91.7 98.0 98.9
Percentage of PD-1+ cells in stroma, not close to tumor (20µm) (%) 88.3 95.0 96.8
*Indicates the number of cells or areas from the two consecutive slides (CD3 and PD-1, respectively).
FIGURE 5 | PGE2 inhibits T-cell proliferation and upregulate co-inhibitory markers on proliferating T-cells. CFSE-labeled PBMCs were cultured in the absence (•) or
presence (×) of 0.1µg/ml PGE2 and stimulated with OKT3 (25 ng/ml) for 5 days (n = 8). (A) Frequency of proliferating CD4
+ and CD8+ T-cells (left). Representative
CFSE histograms on CD4+ T-cells (right). Expression of (B) TIM-3, (C) PD-1, (D) TIM-3 and PD-1 (E) LAG-3, and (F) HLA-DR on proliferating T-cells. Lines between
dots indicate paired samples. Wilcoxon matched-pairs signed rank test was used to detect statistically significant differences *P < 0.05, **P < 0.01, ns (not significant).
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cells. Furthermore, PD-1 expressing cells were predominantly
localized to the stroma, suggesting a role for CAFs in the
upregulation of PD-1 also in vivo.
PGE2 Upregulates the Expression of
Immune Checkpoints in
Proliferating T-Cells
Since we found that the immunemodulatory activity of CAFs was
at least partly mediated by COX-2 (Figure 2), we next examined
the impact of PGE2 on T-cell proliferation and expression of co-
inhibitory markers. The concentration of PGE2 used was similar
as in previously reported studies (27). As previously shown by
others (28), we found that PGE2 inhibits T-cell proliferation
(Figure 5A), but we also found that it promoted the up-
regulation of TIM-3 and PD-1 and consequently co-expression
of TIM-3 and PD-1 on T-cells (Figures 5B–F). However, no
effect on LAG-3 expression was observed (Figure 5E). PGE2 also
decreased the expression of HLA-DR in CD8+ T-cells, but not
significantly in CD4+ T-cells (Figure 5F). The median reduction
in proliferation after addition of PGE2 was 1.7- and 2.7-fold
for CD4+ and CD8+ T-cells, respectively, which can be put in
comparison to CAF-mediated suppression of a median of 2.6-
fold for CD4+ T-cells and 2-fold for CD8+ T-cells (Figure 2A).
T-Cells Expressing Co-inhibitory Markers
Are Less Functional in the Presence
of CAFs
Co-inhibitory receptors are associated with T-cell exhaustion,
but they can also indicate T-cell activation and differentiation.
Having shown that CAFs upregulate the expression of co-
inhibitory receptors on proliferating T-cells, we investigated
whether CAFs alter the cytokine production of T-cells expressing
PD-1 and/or TIM-3. After initial stimulation of T-cells in the
presence or absence of CAFs for 5 days, T-cells were restimulated
with PMA/Ionomycin for 6 h. Figure 6 shows that proliferating
CD8+ T-cells expressing the co-inhibitory markers PD-1, TIM-3
or co-expressing both PD-1 and TIM-3 expressed less CD107a
and IFN-γ in the presence of CAFs in all paired samples
(Figures 6A,B). In addition, CD8+ T-cells expressing PD-1
contained lower levels of TNF-α (Figure 6C). The same pattern
was also observed for CD4+ T-cells (data not show). Thus, this
indicates that the CAPSC-mediated expression of co-inhibitory
markers leads to loss of T-cell effector functions.
When we examined the intensity of expression of PD-1
and TIM-3 on proliferating T-cells, we found that CD8+ T-
cells that had been cultured in the presence of CAFs had a
higher median fluorescence intensity (MFI) expression of these
markers (Figure 6D). Thus, this could suggest that the decreased
functional effect observed above could be due to a higher
intensity of expression of PD-1 and TIM-3.
We next examined the impact of CAFs on the memory
phenotype of the proliferating CD3+ T-cells. After stimulation
with OKT3 in the absence of CAFs, a large proportion of
the T-cells differentiated into effector (CD45RA−CCR7−) or
central (CD45RA−CCR7+) memory T-cells. In the presence
of CAFs, a larger proportion of the T-cells retained their
naïve phenotype (CD45RA+CCR7+) compared to T-cells
cultured in the absence of CAFs, and a smaller proportion
of the T-cells adopted an effector memory phenotype
(Figures 6E,F). Similar results were found when using a
transwell system (Supplementary Figure S5H). Together,
these results suggest that CAF-derived soluble factors are
able to suppress differentiation of effector memory T-
cells, which may further explain the decreased functional T
cell response.
PD-1 Expression Is Negatively Correlated
to the Proliferative Capacity of CD8+
T-Cells in the Presence of CAFs
To determine which co-inhibitory markers that was most
strongly affected by CAFs, we performed a multiple comparison
test on pooled data from different experiments. As shown
in Figure 7A, co-expression of PD-1 and TIM-3 followed by
expression of PD-1 were the markers that was most strongly
increased after co-culture with CAFs. This suggests that among
the markers we have studied here, PD-1 is the factor that is most
affected by CAFs.
To investigate how the expression pattern of co-inhibitory
markers affects proliferation of CD8+ T-cells, we used the pooled
data from different experiments to generate a correlation matrix.
As shown in the correlation heat maps depicted in Figures 7B–C,
we found that the pattern looked different depending on whether
CAFs had been added to the cultures or not. In the presence of
CAFs, proliferation was negatively associated to the expression
of PD-1 and to co-expression of PD-1 and TIM-3 (Figures 7C,E),
but proliferation was not significantly correlated to these factors
in the absence of CAFs (Figures 7B,D). In contrast, proliferative
responses were positively correlated to TIM-3 in the presence of
CAFs (Figures 7C,E), but not in CD8+ T-cells cultured without
CAFs (Figures 7B,D). LAG-3 was not associated to proliferation,
but there was a trend for a negative association between LAG-
3 and proliferation in T-cells stimulated in the absence of CAFs
(r =−0.47 and P = 0.07) (Figure 7B).
Furthermore, in CD8+ T-cells cultured in the presence
of CAFs, we found that PD-1 expression and co-expression
of PD-1 and TIM-3 was negatively correlated to LAG-
3 expression (Figures 7C,F). The late activation marker
HLA-DR was also negatively correlated to PD-1 and TIM-
3 co-expression (r = −0.36, p = 0.035), and the same
trend was seen for PD-1 expression (r = −0.33, p = 0.053)
(Figure 7C). In line with this, LAG-3 expression was positively
associated to HLA-DR expression (Figures 7C,F), which
was evident also in the absence of CAFs (Figure 7B). This
suggest that LAG-3 is associated with activation, rather than
co-inhibition, under these experimental settings. Finally,
the expression of PD-1 was correlated to PD-1+TIM-
3+ T-cells, both in the presence and absence of CAFs
(Figures 7B,C,F), indicating that the majority of PD-1+ T-
cells also express TIM-3. Together, this points to a complexity
in the function of co-inhibitory marker expression and T-
cell proliferation, but also suggests that the CAF-mediated
upregulation of PD-1 play a key role in suppressing CD8+ T cell
proliferation. However, further functional assays are needed to
confirm this.
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FIGURE 6 | CAFs promote non-functional T-cells. CFSE-labeled PBMCs were co-cultured in the absence (•) or presence (N) of CAFs and stimulated with OKT3
(25 ng/ml). On day 5 PBMCs were re-stimulated with PMA/Ionomycin (I) for 6 h. Expression of (A) CD107a and (B) IFN-γ in PD-1+, TIM-3+ and PD-1+TIM-3+ CD8+
T-cells (n = 12). (C) Expression of TNF-α in PD-1+ CD8+ T-cells (n = 8) (upper). Representative dot plots showing the gating strategy in (A–C) (bottom). (D) Median
fluorescence intensity (MFI) of PD-1 and TIM-3 expression on CD8+ T-cells. (E) Pie charts with proportions of CD3+ T-cell memory subsets in unstimulated and
proliferating T-cells after OKT3 stimulation. (F) Frequency of CD45RA+ CCR7+ (naïve), CD45RA− CCR7+ (central memory), CD45RA− CCR7− (effector memory),
CD45RA+ CDR7− (terminally differentiated) expressed as percentage of proliferating CD3+ T-cells (n = 6) in the presence or absence of CAFs (left). Flow cytometry
gating strategies for naïve (N), central memory (CM), effector memory (EM) and terminally differentiated (TD) on proliferating CD3+ T-cells (right). Lines between dots
indicate paired samples. Wilcoxon matched-pairs signed rank test was used to detect statistically significant differences *P < 0.05, **P < 0.01, ***P < 0.001.
DISCUSSION
Tumors have developed several strategies to escape anti-
tumor immunity, including physical barriers and recruitment
of immunosuppressive cells. In pancreatic cancer, the tumor
microenvironment is dominated by a dense stroma created by
activated CAFs, which mediate tumor growth and progression
by producing extracellular matrix proteins, growth factors,
chemokines, and cytokines. Numerous studies have explored
the immunosuppressive properties of CAFs and their role in
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FIGURE 7 | CAF-induced expression of PD-1 is negatively associated to CD8+ T-cell proliferation. (A) Multiple comparison test between expression of different
co-inhibitory markers on CD8+ T-cells in the absence (black) or presence (orange) of CAFs after OKT3 stimulation (n = 40 for TIM-3 and PD-1, and n = 16 for LAG-3)
(Continued)
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FIGURE 7 | in pooled experiments. (B,C) Heat map correlation matrix showing positive (orange) and negative (black) correlations between proliferation and
co-inhibitory marker expression in OKT-3 stimulated CD8+ T-cells (n = 40 for proliferation, TIM-3 and PD-1, n = 16 for TIM-3, and n = 34 for HLA-DR) in the (B)
absence or (C) presence of CAFs. (D,E) Correlations between proliferation and TIM-3, PD-1, and PD-1 and TIM-3 expression in the absence or presence of CAFs.
(F) Correlation between expression of LAG-3 and expression of PD-1, and HLA-DR on T-cells cultured in the presence of CAFs. (F) Correlations between expression
of PD-1 and co-expression of PD-1 and TIM-3 in CD8+ T-cells cultured in the presence of CAFs. Friedman’s test followed by Dunn’s test was used to evaluate
significant difference between groups. Correlations were evaluated by using Spearman’s correlation test. Spearmen r and p-values are presented.
supporting tumor cell growth by favoring the presence of tumor
promoting immune cells [reviewed in Ziani et al. (29)]. However,
most studies have focused on the effect of CAFs on the innate
immune cells, rather than on the adaptive immune response.
Since T-cells are the dominant immune cell subset with a
potential capacity to eradicate tumor cells, we have performed
an in-depth examination of how CAFs affect the phenotype
and activation status of T-cells. One of the most interesting
findings was that CAFs induce the expression of the co-inhibitory
markers TIM-3, PD-1, CTLA-4, and LAG-3 on activated T-cells
upon stimulation. We further identified PGE2 as an inducer of
co-inhibitory marker expression. In addition, T-cells expressing
immune checkpoints produce less IFN-γ, TNF-α, and CD107a
after restimulation when CAFs had been present, suggesting
that CAPCSs promote T-cell exhaustion that leads to functional
incapacity. We used OKT3 as a stimulation since it is commonly
used to study T cell activation and due to that it is difficult to
find a more physiological stimuli that universally activates T-cells
from different donors.
The phenotype and function of CAFs can be altered during
in vitro cultivation and expansion. However, fibroblasts from
different anatomical sites of the body have been shown to have
distinct transcriptional patterns even after in vitro expansion,
indicating a positional memory of stromal cells (30). We
compared the phenotype of CAFs throughout passages 1 and
up to 3, but no apparent differences were observed. To
limit the potential variation by the phenotype throughout the
experiments, all the fibroblasts used in the study were in passage
3. The high expression of the cancer-associated markers FAP
and podoplanin in normal skin fibroblasts, could suggest an
upregulation of somemarkers through serial passaging. However,
the activation marker α-SMA was only expressed in CAFs.
Pancreatic CAFs display heterogeneity and several subtypes
of CAFs have been identified in pancreatic cancer. Öhlund
et al. have described two dynamic subsets of pancreatic CAFs
based on the expression of α-SMA (6). A subpopulation of α-
SMAhigh myofibroblasts were predominantly localized in close
proximity with tumor cells, while α-SMAlow cells represented
inflammatory CAFs associated with elevated expression of tumor
promoting cytokines, including IL-6, and were located more
distantly from the tumor cells. Biffi et al. further showed that
tumor-derived TGF-β is involved in driving differentiation into
myofibroblasts, whereas IL-1 signaling via JAK/STAT activation
promoted inflammatory CAFs (7). TGF-β also counteracted the
differentiation of inflammatory CAFs. Furthermore, Neuzillet
recently demonstrated the presence of at least four different
subpopulations of pancreatic CAFs, which can be distinguished
based on the expression of periostin, podoplanin, and myosin-
11, and were also associated to prognostic impact (8). Thus,
it can be speculated that both pro-tumorigenic and anti-
tumorigenic subtypes of CAFs are present in pancreatic cancer.
The CAFs studied here are likely a combination of different CAF
subpopulations, and there was also an inter-individual variation
in the expression of the majority of the markers investigated,
including α-SMA and podoplanin. Fur future studies, it would
be interesting to examine how different subpopulations of CAFs
affect T-cell responses.
The binding interaction between PD-1, expressed on
activated T-cells, and its co-regulatory ligands PD-L1 and PD-L2
has previously been suggested as a mechanism underlying the
suppressive effects of fibroblasts (11, 25, 31, 32). Moreover,
Shibuya et al. reported that the majority of TILs in pancreatic
cancer express PD-1 (33), suggesting that PD-L1/PD-1
interactions can modulate T-cell cytotoxic functions in this
malignancy (34). PD-L1 overexpression has been reported in
PDAC and it has also been correlated with poor overall survival
outcome (34–36). However, few studies have explored the
expression PD-L1 and PD-L2 in human carcinoma fibroblasts. In
our study, we show by flow cytometry that CAFs constitutively
express PD-L1 and PD-L2 in a higher frequency than normal
skin fibroblasts and that the expression varies greatly between
patients. We further noted that PD-L2, rather than PD-L1, was
the dominant PD-1 ligand. Nazareth et al. also showed abundant
levels of PD-L1 and PD-L2 in a subset of fibroblasts obtained
from non-small cell lung carcinoma (32), and another study by
Takahashi et al. showed a modest, but constitutive, expression
of these ligands in fibroblasts from head and neck squamous
cell carcinoma (11). We found that blockade of these ligands
partially restored the proliferative ability of CD4+ T-cells, which
was also observed for CD8+ T-cells in 65% of the experiments.
Studies by Nazareth et al. and Takahashi et al. could also restore
the T-cell suppression in some samples. The difference in the
expression and function of PD-L1 and PD-L2 within a tumor
and between tumors further strengthen the general perception
that fibroblasts are a diverse group of cells and its functional
activity might vary depending on the tumor microenvironment
and the cytokine milieu.
Even though the CAFs secretome is still not completely
characterized, there is evidence that the wide variety of growth
factors and cytokines released by CAFs play a major role
in orchestrating tumor progression and immune evasion (4).
Since our transwell assays indicated that the immunosuppressive
effects of CAFs are mediated by soluble factors, we attempted
to identify factors involved in T-cell suppression by blocking the
activity of the known soluble immunosuppressive factors PGE2,
TGF-β, and IDO. PGE2, the major metabolite of the COX-2
enzyme, is known for its role to promote tumor growth, survival,
invasion, angiogenesis, and suppression of anti-tumor immunity
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(37, 38). However, little is still known about the importance
of PGE2 in the context of CAF–mediated immunosuppression.
The expression of COX-2 in fibroblasts from pancreatic cancer
(23, 39) and other tumor types (40, 41) has been previously
reported. Here, we show that by blocking PGE2 production with
indomethacin, T-cell proliferation was partially restored and the
positive effect was consistent in all paired samples. No increased
effect in proliferation was observed when both the COX-2 and the
PD-1 axis was blocked, suggesting that the COX-2 inhibition is
the most important pathway. However, there is also a possibility
that the CAFs upregulate even higher levels of the PD-1 ligands
during the in vitro culture, which could reduce the efficacy of
PD-1 axis blockade using neutralizing antibodies. PD-L1/PD-
L2 knock-out experiments could be a better approach to fully
explore the importance of the PD-1 axis in CAF-mediated T-
cell suppression.
IDO and TGF-β are also expressed by CAFs (4, 24) and they
can contribute to immune evasion by catabolizing tryptophan
into a number of downstream immunosuppressive metabolites
(42) and by targeting cytotoxic T-cell functions (43), respectively.
However, T-cell proliferation was not affected by blocking these
molecules in our system. This does not exclude the possibility
that these molecules exert a negative regulatory activity in
vivo. Fibroblast-derived soluble factors can modulate the tumor
microenvironment by recruiting other immune cells, which
in turn secrete more immunosuppressive cytokines, creating
autocrine and paracrine loops which can interfere with T-
cell activity (29, 44). Here, in line with previous studies we
found that the proportion of CD4+FOXP3+ putative Tregs was
significantly increased when CAFs were added to unstimulated
PBMCs. This was also accompanied by increased levels of
the immunosuppressive cytokine IL-10 in the supernatants,
but the source of IL-10 remains to be determined. An
association between tumor infiltrating FOXP3+ Tregs and a
dismal prognosis has been shown in several cancers. Kinoshita
et al. demonstrated that Tregs were primarily localized to the
stroma in lung adenocarcinoma, and less to the tumor nest, and
that CAFs isolated from tissues with high Treg numbers had a
better FOXP3-inducing effect compared to CAFs from low Treg
adenocarcinomas (26).
There is evidence that CAFs interact with T-cells in the
tumor stroma by skewing the immune response toward Th2
(45), and cross-present antigens which leads to T-cell apoptosis
and dysfunction (31). Studies with murine models have also
reported that CAFs limit the access of CD8+ T-cells to the
tumor (19, 46). However, this perception has been challenged
by studies of stained human tissues samples which show a great
variability of TILs and that the stroma microenvironment does
not affect cytotoxic T-cell infiltration (15, 33). Stromnes et al.
recently showed that the majority of T-cells localize to tertiary
lymphoid structures rather than the tumor nest in many patients
with high T-cell infiltration (47), which is in line with our findings
that the majority of the T-cells reside in the desmoplastic stroma
and that few T-cells are in immediate contact with cancer cells.
Since a recent paper suggested that the desmoplastic stroma
does not prevent T-cells from entering the tumor nests (15),
we analyzed the distribution of T-cells and PD-1 expressing
cells and also included cells that was in close proximity to the
tumor cells. Although the number of patients analyzed are low,
the data consistently shows that over 90% of all T-cells in the
tumor microenvironment are localized to the stroma, and that
inclusion of T-cells that are close enough to potentially interact
with tumor cells only marginally increase the estimated T-cell
density in tumors.
Regardless of the existence of TILs in pancreatic cancer and
the fact that high number of TILs correlates with an increased
overall survival (15, 16, 19), the prognosis is still dismal (1).
This can partly be explained by that CAFs, together with
tumor-infiltrating Tregs, M2 macrophages, and myeloid derived
suppressor cells, create an immunosuppressive tumor milieu that
inhibits the activation and function of effector T-cells (48, 49).
Here, we have further explored the interactions between T-cells
and CAFs and show, for the first time to our knowledge, that
CAFs promote the expression of the co-inhibitory markers TIM-
3, PD-1, CTLA-4 and LAG-3 on activated T-cells. Since CAFs
markedly suppressed the proliferation of T-cells, we reasoned
that the most fair way to compare the T-cell phenotypes
would be to only study T-cells that respond to the stimulation,
e g proliferating cells. In a more physiological setting, this
would only apply to T-cells that have gone through clonal
expansion after encountering their antigen. Our findings from
the immunohistochemistry stainings of tumor tissue also suggest
that PD-1+ T-cells can be found in close proximity to tumor cells
but also to α-SMA+ CAFs. Thus, considering the high levels of
PD-L1/L2 on CAFs, one could speculate that CAFs effect T-cell
functionality in vivo upon PD-L1/L2 binding.
It has previously been proposed that the co-expression
of inhibitory receptors rather than individual expression is
indicative of T-cell exhaustion (50). We found a 5.9-fold and a
2.7-fold increase in the frequency of CD4+ and CD8+ T-cells,
respectively, co-expressing TIM-3, PD-1 and CTLA-4 and a 2.3-
fold and a 1.7-fold increase in the frequency of CD4+ and CD8+
T-cells, respectively, co-expressing TIM-3, PD-1 and LAG-3. We
also observed that the proliferating T-cells positive for PD-1,
TIM-3, or double positive for PD-1 and TIM-3 expressed lower
levels of the degranulation marker CD107a and reduced levels
of the inflammatory cytokines IFN-γ and TNF-α when CAFs
had been present. The low cytokine production could also be
explained by the fact that most of the proliferating T-cells retain
their naïve phenotype in the presence of CAFs. Thus, although
some T-cells differentiate into a central memory phenotype,
they fail to fully differentiate into cytotoxic effector memory T-
cells. We used the expression of CD107a as a marker for T-
cell degranulation, which previously have been shown to be a
good surrogate marker for cytolytic activity (51). However, it
still needs to be determined if CAFs diminishes the capacity
to kill tumor cells in an antigen-specific manner. Considerable
research has been devoted to investigate how tumor cells achieve
immune evasion by interacting with T-cell co-inhibitory markers
(52). However, less attention has been paid on the impact of the
tumor stroma fibroblasts on T-cell functions. It remains to be
determined if our findings that CAFs are capable to disarm T-
cell effector functions and promote upregulation of co-inhibitory
markers are also relevant in vivo.
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Among the co-inhibitory markers that we have studied
here, PD-1 and co-expression of PD-1 and TIM-3 were most
strongly affected by pancreatic CAFs. Correlation analyses
further indicated that PD-1 expression and co-expression of
PD-1 and TIM-3 were negatively associated to proliferative
capacity of CD8+ T-cells that had been cultured with CAFs.
On the other hand, TIM-3 and LAG-3 expression was not
associated to less proliferation, but rather to increased activation
as determined both by HLA-DR expression and proliferation.
Thus, the function of co-inhibitory markers is complex in
activated T-cells, but it highlights an important role for PD-1
expression in the CAF-mediated suppression of T-cells.
We used allogeneic PBMC in the majority of the experiments,
and one could argue that the MHC-mismatch between the
PBMCs and CAFs could affect the response of the assay.
However, very similar results were observed in transwell settings,
suggesting that response to alloantigens are not affecting the
assay. This also was confirmed in a number of experiments using
autologous patient-derived PBMCs.
It has been reported that the expression of PD-1 on TILs
is correlated with increased PGE2 levels in lung cancer (27).
Since we showed that COX-2 inhibitors partially restored
T-cell proliferation, we investigated whether adding PGE2
to PBMCs cultures induced co-inhibitory molecules on
proliferating T-cells. Indeed, we observed that PGE2 inhibits
T-cell proliferation and upregulates the expression of both
PD-1 and TIM-3 on proliferating T-cells. These results are in
line with previous studies showing that exhausted cytotoxic
T-lymphocytes upregulate the expression of PGE2 receptors
EP2 and EP4 (53) and that the combined inhibition of PD-
1 signaling pathway and PGE2 increased the number and
the cytotoxic effects of CD8+ T-cells (53). Interestingly in
this context, COX-2 inhibitors have been shown to inhibit
pancreatic stellate cell proliferation and activation (54).
However, treatment with the COX-2 inhibitor celecoxib in
combination with standard chemotherapy for pancreatic
cancer did not show any clinical benefits (55). On the other
hand, others have shown that inhibition of COX2 potentiates
the effect of anti-PD-1 blockade in experimental models of
melanoma, indicating that COX inhibitors could function as
an adjuvant for immune checkpoint inhibition (38). Since it
has been documented that T-cells tend to upregulate other
co-inhibitory markers after PD-1 blockade, notably TIM-3 (56),
our findings that PGE2 upregulate TIM-3 further strengthen
the clinical relevance of combining COX inhibitors with
anti-PD-1 treatment.
In order to find a successful cure for PDAC, it will be
important to delineate the mechanisms behind the functional
defects of TILs. It will likely involve several different treatment
approaches, and our findings suggest that it is important
to investigate the complex interactions between the CAFs
and T-cells. An increased understanding of how fibroblasts
from tumor tissues affect T-cell phenotype and functions
could lead to the development of improved combined
immunotherapy strategies.
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